Line 01Recovery & Repair
BPC-157, TB-500, and KPV are studied for processes involved in tissue repair, gastric protection, and inflammatory modulation. Your clinician considers your health history and recovery goals when assessing whether a protocol is appropriate.
BPC-157Body Protection Compound
503A rec · Jul 2026Evaluated by the FDA's compounding advisory committee for ulcerative colitis and recommended for the 503A bulks list. Research centers on gastric protection and soft-tissue repair.
View a sample COA
TB-500Thymosin Beta-4 fragment
503A rec · Jul 2026A peptide studied for its role in cell migration and tissue organization. Recommended for wound healing in July 2026, with final FDA rulemaking pending. Often prescribed alongside BPC-157 as separate compounds your clinician can adjust independently.
View a sample COA
KPVLysine-Proline-Valine
503A rec · Jul 2026A natural fragment of α-MSH studied for inflammatory modulation and antimicrobial activity, including oral and topical routes. Recommended in the July 2026 committee vote for inflammatory conditions and wound healing, with final FDA rulemaking pending.
View a sample COALine 02Metabolic
MOTS-c is studied for metabolic regulation and signaling associated with exercise. It is WADA prohibited and unavailable to competitive athletes.
MOTS-cMitochondrial-derived peptide
503A rec · Jul 2026Studied for metabolic regulation and exercise-mimetic signaling; evaluated for obesity and bone density. We publish net peptide content on every MOTS-c lot.
View a sample COALine 03Sleep & Circadian
Epitalon is studied for circadian regulation and telomere biology. It is considered within a full sleep and recovery assessment.
EpitalonEpithalon
503A rec · Jul 2026A synthetic tetrapeptide studied for circadian regulation and telomere biology. Recommended with insomnia as the evaluated indication, with final FDA rulemaking pending. Considered only as part of a full sleep and recovery assessment.
View a sample COALine 04Cognitive
Semax is studied for neuroprotective and cognitive effects. Prescribing requires a neurological history review; it is not a performance enhancer or a substitute for care.
SemaxACTH fragment analogue
503A rec · Jul 2026Studied for neuroprotective and cognitive effects; evaluated for migraine and cerebral ischemia. Prescribed only after a review of your neurological history. Never marketed as a performance enhancer or a substitute for care.
View a sample COALine 05Skin & Topical
Topical GHK-Cu is studied for dermal remodeling and collagen support. Injectable GHK-Cu remains under review and is not offered.
GHK-CuCopper tripeptide · topical
Category 1 · topicalExtensively studied in dermal remodeling and collagen support; moved to the FDA Category 1 list for topical use in May 2026. Injectable GHK-Cu remains under review. We will not offer it unless a lawful compounding pathway is established.
View a sample COALine 06Body Composition
Tesamorelin is studied for effects on body composition, with prescribing based on an individual assessment and contraindication screening. No equivalence to a branded product is claimed; it is WADA prohibited and unavailable to competitive athletes.
TesamorelinGHRH analogue
FDA-approved componentThe active ingredient in an FDA-approved prescription medication. Compoundable for individual patients under Section 503A today. Prescribing is strictly individualized; we make no equivalence claims about any branded product.
View a sample COAProtocols are combined by clinicians only.
Only your clinician can determine whether a protocol is appropriate or whether separate protocols should be combined. Each compound requires an individual prescription and a lawful compounding pathway; we do not offer fixed-dose blends.
Committee recommendations remain subject to final FDA rulemaking. WADA restrictions apply, and prohibited compounds are not available to competitive athletes.